Free Trial
NASDAQ:ANL

Adlai Nortye (ANL) Stock Price, News & Analysis

Adlai Nortye logo
$2.26 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.25 -0.01 (-0.44%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adlai Nortye Stock (NASDAQ:ANL)

Key Stats

Today's Range
$2.20
$2.33
50-Day Range
$1.95
$2.69
52-Week Range
$1.85
$17.48
Volume
6,021 shs
Average Volume
9,011 shs
Market Capitalization
$83.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Adlai Nortye Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

ANL MarketRank™: 

Adlai Nortye scored higher than 56% of companies evaluated by MarketBeat, and ranked 481st out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adlai Nortye has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Adlai Nortye has received no research coverage in the past 90 days.

  • Read more about Adlai Nortye's stock forecast and price target.
  • Earnings Growth

    Earnings for Adlai Nortye are expected to decrease in the coming year, from ($0.88) to ($0.92) per share.

  • Percentage of Shares Shorted

    0.01% of the float of Adlai Nortye has been sold short.
  • Short Interest Ratio / Days to Cover

    Adlai Nortye has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adlai Nortye has recently decreased by 13.64%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Adlai Nortye does not currently pay a dividend.

  • Dividend Growth

    Adlai Nortye does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of Adlai Nortye has been sold short.
  • Short Interest Ratio / Days to Cover

    Adlai Nortye has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adlai Nortye has recently decreased by 13.64%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Adlai Nortye has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Adlai Nortye this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for ANL on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adlai Nortye insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 35.21% of the stock of Adlai Nortye is held by institutions.

  • Read more about Adlai Nortye's insider trading history.
Receive ANL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adlai Nortye and its competitors with MarketBeat's FREE daily newsletter.

ANL Stock News Headlines

ANL Adlai Nortye Ltd.
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Adlai Nortye Ltd. (ANL)
Adlai Nortye Announces CFO Transition with Interim Appointment
See More Headlines

ANL Stock Analysis - Frequently Asked Questions

Adlai Nortye's stock was trading at $2.69 at the beginning of 2025. Since then, ANL shares have decreased by 16.0% and is now trading at $2.26.
View the best growth stocks for 2025 here
.

Adlai Nortye (ANL) raised $58 million in an initial public offering on Friday, September 29th 2023. The company issued 2,500,000 shares at a price of $23.00 per share.

Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adlai Nortye investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), nCino (NCNO), Construction Partners (ROAD), Taiwan Semiconductor Manufacturing (TSM) and XPeng (XPEV).

Company Calendar

Today
2/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ANL
Previous Symbol
NASDAQ:ANL
Fax
N/A
Employees
127
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+298.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$83.39 million
Optionable
Not Optionable
Beta
-1.41
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ANL) was last updated on 2/28/2025 by MarketBeat.com Staff
From Our Partners